From: Risk factors for early progression of diffuse low-grade glioma in adults
Variable | Recurrence (n = 80) | Non-recurrence (n = 58) |
---|---|---|
Sex, n (%) | ||
Male | 39 (48.8) | 28 (48.3) |
Female | 41 (51.2) | 30 (51.7) |
Age, years, n (%) | ||
≥ 40 | 38 (47.5) | 28 (48.3) |
< 40 | 42 (52.5) | 30 (51.7) |
Tumor subtype, n (%) | ||
Astrocytoma | 59 (73.8) | 35 (60.3) |
Oligodendroglioma | 21 (26.2) | 23 (39.7) |
Tumor location, n (%) | ||
Superfical | 60 (75.0) | 47 (81.0) |
Deep | 20 (25.0) | 11 (19.0) |
Tumor range, n (%) | ||
Single lobe | 45 (56.3) | 33 (56.9) |
Multiple lobe | 35 (43.7) | 25 (43.1) |
Preoperative tumor volume, cm3, n (%) | ||
≤ 30 | 26 (32.5) | 29 (50.0) |
> 30 | 54 (67.5) | 29 (50.0) |
EOR, n (%) | ||
100 | 36 (45.0) | 26 (44.8) |
90–100 | 32 (40.0) | 24 (41.4) |
< 90 | 12 (15.0) | 8 (13.8) |
Treatment after first surgery, n (%) | ||
RT alone | 20 (25.0) | 0 (0.0) |
Chemotherapy alone | 16 (20.0) | 9 (15.5) |
RT + chemotherapy | 26 (32.5) | 34 (58.6) |
None | 18 (22.5) | 15 (25.9) |